TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03492437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate
Description: Participants received single oral dose of Dabigatran etexilate on Day 1 of Treatment period 1 and co-administration of Dabigatran with Tepotinib on Day 8 of Treatment period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate
Description: Participants received single oral dose of Dabigatran etexilate on Day 1 of Treatment period 1 and co-administration of Dabigatran with Tepotinib on Day 8 of Treatment period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Participants received single oral dose of Tepotinib for 8 days in Treatment period 2.
Study: NCT01256528

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed Breast Reconstruction
Description: Approximately 3 months after postmastectomy radiation therapy, the preserved, irradiated, and re-inflated breast skin will be used to perform the delayed breast reconstruction. During the stage 2 reconstruction, the implant or expander will be removed and the definitive reconstruction will be performed with the preserved breast skin utilizing a preference for autologous tissue or autologous tissue with an implant due to the potential for complications with implant-based reconstructions after radiation therapy (XRT).
Study: NCT01299350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nt-proBNP guided discharge
Description: Every patient will receive the drug treatment indicated in the guidelines of the European Society of Cardiology. Patients will be discharged the third day if NT-proBNP levels drops \>30% compared to admission values. If such a reduction is not achieved, then the pharmacological treatment will be increased and NT-proBNP will be measured the following days until reaching the 30% reduction. The cutoff point of 30% reduction in NTproBNP was chosen based on previous studies
Study: NCT00667329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2CdA
Description: 1.5 mg/m\^2 subcutaneous injection three times daily x 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 40 mg/m\^2 PO twice daily x 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 IV once weekly x 4 weeks.
Study: NCT02752815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Study: NCT02371590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide is administered orally once daily on Days 8-28 of each 28 day cycle. The starting dose for all patients is 5 mg PO daily. At the start of each cycle, there is intra-patient dose-escalation to a maximum of 25mg daily, as tolerated.~The study consists of a 6 month treatment period with obinutuzumab and lenalidomide, and an indefinite period of treatment with lenalidomide for as long as it is helpful and tolerated by subject.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab is administered as follows: Cycle 1: 100mg IV on day 1, 900 mg IV on day 2, 1000mg day 8, 1000 mg on day 15. Cycles 2-6: 1000mg IV on day 1.
Study: NCT02642562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Derisomaltose
Study: NCT01739439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hyperfractionated radiation therapy
Description: Undergo hyperfractionated IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo hyperfractionated IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiosurgery
Description: Undergo radiosurgery boost
Study: NCT03506438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Needs-focused mobile app
Description: A mobile web app designed to assist both ICU clinicians in addressing patient/family needs and families in reporting their unmet needs.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Usual ICU care as per the standards of the ICU attending
Study: NCT00823264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Activated Charcoal
Description: 50 grams by mouth every 4 hours until serum phenytoin level is less than 25.
Study: NCT04657939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Liraglutide 0.6mg once daily by subcutaneous injection escalated to 1.2mg after 2 weeks.
Study: NCT01739439

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diffusion-weighted magnetic resonance imaging
Description: Correlative studies
Study: NCT01370590

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 20 mg tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: 10 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe/atorvastatin
Description: Ezetimibe/atorvastatin 10 mg/20 mg combination tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to atorvastatin
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to ezetimibe
Description: Administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to ezetimibe/atorvastatin
Description: Administered orally once daily
Study: NCT00588900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study: NCT01717742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPA (Tissue Plasminogen Activator)
Description: Intrapleural administration of tPA 4 mg in 10 ml (≤10 kg) or 20 ml (\>10 kg) normal saline once daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPA (Tissue Plasminogen Activator)
Description: Intrapleural administration of tPA 4 mg in 10 ml (≤10 kg) or 20 ml (\>10 kg) normal saline once daily for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNase
Description: Intrapleural administration of DNase 5 mg diluted to 10 ml (≤10 kg) or 20 ml (\>10 kg) normal saline once daily for 3 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Intrapleural administration of normal saline 10 ml (≤10 kg) or 20 ml (\>10 kg)
Study: NCT03397875

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Zinc oxide based sealer
Description: After root canal treatment obturation will be done using zinc oxide eugenol based sealer.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epoxy resin based sealer
Description: After root canal treatment obturation will be done using epoxy resin based sealer.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bioactive silicone based sealer
Study: NCT03877497

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adapted SBIRT-T for transgender women
Description: Transgender women will be screened for substance use. Those at moderate risk or less will be randomized into the study into either the intervention arm (SBIRT-A) or the control arm (CONTROL-C). Those at higher risk will be ineligible for the study and referred for substance use treatment services

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted SBIRT-T for transgender women
Description: Transgender women will be screened for substance use. Those at moderate risk or less will be randomized into the study into either the intervention arm (SBIRT-A) or the control arm (CONTROL-C). Those at higher risk will be ineligible for the study and referred for substance use treatment services
Study: NCT03621787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant insertion device
Description: Device designed to assist healthcare providers in administering subcutaneous implants safely and accurately.
Study: NCT02906163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymalfasin (Thymosin alpha 1, Ta1)
Description: In Phase I patients will be randomized to one of two different dosing regimens of Thymosin alpha 1 for a treatment duration of 4 months. At the completion of Phase I, data will be reviewed and a single dosing regimen will be carried forward into Phase II.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymalfasin (Thymosin alpha 1, Ta1)
Description: In Phase I patients will be randomized to one of two different dosing regimens of Thymosin alpha 1 for a treatment duration of 4 months. At the completion of Phase I, data will be reviewed and a single dosing regimen will be carried forward into Phase II.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SoC (tyrosine kinase inhibitor)
Description: In Phase II patients will be randomized to SoC or Thymosin alpha 1 plus SoC for treatment duration of 12 months. All patients will be followed for approximately 18 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SoC (tyrosine kinase inhibitor)
Description: In Phase II patients will be randomized to SoC or Thymosin alpha 1 plus SoC for treatment duration of 12 months. All patients will be followed for approximately 18 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SoC (tyrosine kinase inhibitor)
Description: In Phase II patients will be randomized to SoC or Thymosin alpha 1 plus SoC for treatment duration of 12 months. All patients will be followed for approximately 18 months.
Study: NCT04657939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 15mg once daily tablets taken orally escalated to 30mg after 2 weeks then escalated to 45mg after another 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 15mg once daily tablets taken orally escalated to 30mg after 2 weeks then escalated to 45mg after another 2 weeks.
Study: NCT00032448

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standardized tension-free herniorrhaphy with prosthesis
Description: Compare the effect of two typs of operative treatment of inguinal hernia.
Study: NCT04131920

Intervention type: DEVICE
Intervention: handheld ultrasound: Philips Lumify integrated tele-ultrasound powered by Reacts collaborative platform
Description: Patients receive training by the physical therapist to operate a handheld ultrasound (HHUS) including proper probe placement. Subjects will be tested on their knowledge at the HTC to demonstrate proficiency, and will then repeat the testing at home via tele-ultrasound.

Intervention type: DEVICE
Intervention: handheld ultrasound: Philips Lumify integrated tele-ultrasound powered by Reacts collaborative platform
Description: Patients receive training by the physical therapist to operate a handheld ultrasound (HHUS) including proper probe placement. Subjects will be tested on their knowledge at the HTC to demonstrate proficiency, and will then repeat the testing at home via tele-ultrasound.
Study: NCT00994110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide (SOM230)
Description: Patients will receive subcutaneous injection of SOM230 or placebo (NS, equivalent volume) on the day of operation prior to resection in the pre-surgical center. The initial subcutaneous injection of drug or placebo will be given at least one hour prior but no longer than 8 hours prior to transection of the pancreas. Patients will be continuously monitored in the OR following this dose administration, and both their cardiac and respiratory status will be closely followed.~Postoperatively patients will receive study drug or placebo every 12 hours. Subcutaneous injections will continue until postoperative day 7, with the last dose administered in the evening on postoperative day 6, or until a pancreatic complication has been identified.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients will receive subcutaneous injection of SOM230 or placebo (NS, equivalent volume) on the day of operation prior to resection in the pre-surgical center. The initial subcutaneous injection of drug or placebo will be given at least one hour prior but no longer than 8 hours prior to transection of the pancreas. Patients will be continuously monitored in the OR following this dose administration, and both their cardiac and respiratory status will be closely followed.~Postoperatively patients will receive study drug or placebo every 12 hours. Subcutaneous injections will continue until postoperative day 7, with the last dose administered in the evening on postoperative day 6, or until a pancreatic complication has been identified.
Study: NCT00827788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodixanol
Description: Iso-osmolar contrast medium (Iodixanol) will be administered during PCI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iopromide
Description: Low-osmolar contrast medium (Iopromide) will be administered during PCI
Study: NCT01591798

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic surgery
Description: Robotic assisted rectal resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic surgery
Description: Laparoscopic assisted rectal resection
Study: NCT02513004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Patients will receive first dose of 90mg ticagrelor tablets (powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure, followed by 90mg of ticagrelor 12 hours after the first dose. The third dose of ticagrelor will be given to patients after the 24 hour blood sample has been obtained and 24 hours after the first dose. Thereafter, the patients will take 90mg of ticagrelor orally bid, at approximately 12-hourly intervals. The total study period is 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Patients will receive a loading dose of 300mg clopidogrel tablets (four 75mg capsules powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure. The second dose of clopidogrel will be given to patients after the 24 hour blood sample has been obtained and 24 hours after the first dose. Thereafter, the patients will take 75mg of clopidogrel capsules orally od. The total study period is 3 months.
Study: NCT02432339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil (MMF)
Description: an immunosuppressant - 500 mgs twice a day for 7 1/2 days - in capsule form

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a sugar pill - 500 mgs twice a day for 7 1/2 days - in the same capsule form as the MMF
Study: NCT02410408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apps Root Cause Analysis or patient safety ISO certification
Description: Apps for conducting RCA or PSC

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: information package
Description: Information on PSC and RCA
Study: NCT02881658

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant sterols-enriched soya beverage provided by Vitasoy
Description: the study product is a 2g plant sterols-enriched in 250ml soya beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soya beverage provided by Vitasoy
Description: the placebo product is a 250 ml soya beverage
Study: NCT02355717

Intervention type: OTHER
Intervention: Observational Study
Study: NCT01055015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flexible dose Q8003 (morphine sulfate and oxycodone hydrochloride)
Description: IR Capsules, flexible dose, every 4 to 6 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)
Description: One 3 mg/2 mg IR Capsule every 4 to 6 hours following a 6 mg/4 mg loading dose.
Study: NCT01644097

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum strain 299v
Description: Given PO

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus probiotic
Description: Given PO

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis probiotic supplement
Description: Given PO
Study: NCT03719430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin is an anthracycline antibiotic with antineoplastic activity 75 mg/m2 IV day 1 (21 day cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX005M
Description: APX005M is a CD40 agonistic monoclonal antibody 0.3 mg/kg IV day 1 (21 day cycles)
Study: NCT02396225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole
Study: NCT01935999

Intervention type: DEVICE
Group type: OTHER
Intervention: One piece closed pouch
Description: A one piece closed pouch for the collection of stool from a colostomy stoma
Study: NCT01214993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: GSK1349572 is an experimental drug in the integrase inhibitor class of drugs to treat human immunodeficiency virus (HIV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: GSK1349572 is an experimental drug in the integrase inhibitor class of drugs to treat human immunodeficiency virus (HIV)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a tablet with no drug in it.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol Injection
Description: Iohexol is an FDA approved radiologic contrast medium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol Injection
Description: Iohexol is an FDA approved radiologic contrast medium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iohexol Injection
Description: Iohexol is an FDA approved radiologic contrast medium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Para-aminohippurate infusion
Description: Para-aminohippurate is an agent to measure effective renal plasma flow.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Para-aminohippurate infusion
Description: Para-aminohippurate is an agent to measure effective renal plasma flow.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Para-aminohippurate infusion
Description: Para-aminohippurate is an agent to measure effective renal plasma flow.
Study: NCT01417468

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLSI, MI, CR
Description: (CLSI) Canfield Learning Styles Inventory (MI) Multiple Intelligences (CR) Cognitive Rehabilitation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CLSI - Unknown
Description: (CLSI) Canfield Learning Styles Inventory (MI) Multiple Intelligences (CR) Cognitive Rehabilitation
Study: NCT03819517

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: Over the counter supplementation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Empty white colored soft vegetarian capsule
Study: NCT03433235

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edoxaban
Description: 1-3-6-12 rule\*~Anticoagulation in patients with acute ischemic stroke and atrial fibrillation can be initiated from the following days after stroke event.~After 1 day: transient ischemic attacks~After 3 days: mild ischemic strokes (NIHSS \<8)~After 6 days: moderate ischemic strokes (NIHSS 8-16)~After 12 days: severe ischemic strokes (NIHSS \>16)~- NIHSS: National Institute of Health Stroke Scales

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: 1-3-6-12 rule\*~Anticoagulation in patients with acute ischemic stroke and atrial fibrillation can be initiated from the following days after stroke event.~After 1 day: transient ischemic attacks~After 3 days: mild ischemic strokes (NIHSS \<8)~After 6 days: moderate ischemic strokes (NIHSS 8-16)~After 12 days: severe ischemic strokes (NIHSS \>16)~- NIHSS: National Institute of Health Stroke Scales
Study: NCT06034093

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time AI-assisted muscle ultrasound
Description: RAIMUS software provides automatic segmentation and size measurement for the RFCSA
Study: NCT02884739

Intervention type: OTHER
Intervention: Data collection

Intervention type: OTHER
Intervention: Data collection
Study: NCT00311688

Intervention type: DRUG
Intervention: Interleukin-2
Description: Biological response modifier in liquid form; dosage of drug will vary by study
Study: NCT02077998

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: carbon C 14 oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02619617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM230
Description: The study evaluated SOM230 vs Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM230
Description: The study evaluated SOM230 vs Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The study evaluated SOM230 vs Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The study evaluated SOM230 vs Placebo
Study: NCT03459716

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention